Amphotericin B inhalation (Nektar Therapeutics)

两性霉素B吸入剂 (Nektar Therapeutics)

Report date: 2026/03/04 20:01:44

Base Information

Drug NameAmphotericin B inhalation (Nektar Therapeutics)
Drug Alias NameNKTR-024
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Macrolides antibiotics
Mechanisms of ActionCell membrane permeability enhancersErgosterol binders
TargetsErgosterol
Therapy Area/IndicationsAspergillosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNektar Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNektar Therapeutics
Active IndicationsN/A
Inactive IndicationsAspergillosis

Other Information

ATC CodeN/A
Related LinksN/A